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A chimeric gene encoding a fusion protein consisting of the DNA-binding domain of the immediate-early (IE) protein of
pseudorabies virus (PRV) and a tail-truncated VP16 of herpes simplex virus 1, lacking the transcription activation domain, has
been shown to repress transcription of the PRV IE gene, resulting in the inhibition of PRV growth in vitro. To assess the
antiviral potential of the fusion protein in vivo, transgenic mice containing the chimeric gene under the control of the virus-
and interferon-inducible Mx 1 promoter were generated. A transgenic mouse line showed marked resistance to PRV infection
when the mice were challenged intranasally with PRV. Inhibition of PRV replication was also observed in monolayers of
embryonic cells prepared from the transgenic mice. In the cells infected with PRV, transcription of the PRV IE gene was
repressed. The present results indicate that the chimeric gene is able to exert a significant antiviral effect against PRV
infection in vivo. © 1999 Academic Press
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iINTRODUCTION
Pseudorabies virus (PRV) of genus Varicellovirus of the
ubfamily Alphaherpesvirinae (Roizman, 1990) causes
evere disease in piglets and leads to latent infection in
ll surviving pigs. PRV infection inflicts serious losses on
he swine industry worldwide. It is also known that PRV
auses acute and often fatal infection in domestic and
ild animals.
PRV expresses a single immediate-early (IE) protein
pecies from two copies of the IE gene that are present
n each inverted repeat region of the viral genome (Ihara
t al., 1983). The coding region of the IE gene is 4380
ucleotides long and codes for 1460 amino acid residues
Cheung, 1989). The product of PRV IE gene, IE180, has
een shown to be a homology of one of the IE gene
roducts, ICP4, of herpes simplex virus 1 (HSV-1)
Cheung, 1989). IE180 functions for continuous transcrip-
ion of late genes and in shutting off the synthesis of their
wn RNA (Kit, 1994), indicating that the IE gene is abso-
utely necessary for productive lytic infection.
“Intracellular immunization” is proposed as an ap-
roach to antiviral therapy in humans and to germ-line
ransformation in animals to confer resistance to virus
nfection (Baltimore, 1988). Intracellular immunization
1 To whom reprint requests should be addressed at Laboratory of
nimal Experiments. Fax: 81-11-757-0715. E-mail: etsuro@imm.hokudai.tc.jp.
042-6822/99 $30.00
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72gainst HSV-1 infection in vivo has been shown by using
mutated form of ICP4 (Smith and DeLuca, 1992). For the
urpose of intracellular immunization against pseudora-
ies, we have set our sights on inhibition of the PRV IE
ene expression. We have shown that the chimeric gene
roduct (Ono et al., 1995) and the dominant-negative
utants of IE180 (Taharaguchi et al., 1994; Ono et al.,
998a) and early protein 0 (EP0) (Watanabe et al., 1996;
asaki et al., unpublished data) can repress transcription
f the PRV IE gene. Among them, the chimeric gene was
ost effective for the purpose. The chimeric gene en-
odes a fusion protein consisting of the DNA-binding
omain of IE180 of PRV and a tail-truncated VP16 of
SV-1, lacking the transcription activation domain.
arked inhibition of PRV replication in the cell lines
ransformed with the chimeric gene has been shown
Ono et al., 1995). The mechanism via which the IE gene
ranscription was inhibited with the fusion protein was
hought to be binding of the fusion proteins to the con-
ensus pentanucleotides (59-ATCGT-39) and/or the oc-
amer sequences on the IE promoter by each binding
omain originating from IE180 and VP16, and the fusion
rotein sterically interfered with the formation of the
ranscription machinery or movement of RNA polymer-
se II.
In the present study, a transgenic mouse line express-
ng the chimeric gene that represses the PRV IE gene
ranscription was established, and resistance to PRV
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73RESISTANCE TO PRV INFECTION IN TRANSGENIC MICEnfection in the transgenic mice was examined to deter-
ine the antiviral potential of the chimeric gene in vivo.
RESULTS
haracterization of transgenic mice
To generate transgenic mice, DNA fragments contain-
ng the chimeric gene were microinjected into C57BL/6
ertilized eggs. In these transgenic mice, the chimeric
ene was expressed under the control of the mouse Mx
promoter, which can be induced by double-stranded
NA, interferon, or virus infection (Fig. 1A). Of the result-
ng 33 births, four animals had the transgene as deter-
ined by Southern blot analysis of tail DNA. In these
ounder mice, one founder had more than five copies of
he transgene per haploid DNA (Fig. 1B). To examine
issue specificity of the transgene expression, mRNA of
he chimeric gene in a variety of organs from the trans-
enic mice was detected by the RT-PCR method. The
ransgene expression was observed in brain, kidney,
ung, and heart (Fig. 1C). In the total lung extract pre-
ared from the transgenic mice after intraperitoneal in-
ection of poly(I)–poly(C), anti-HSV-1 VP16 monoclonal
ntibody-specific band was detected by Western blot
nalysis (Fig. 1D). The other three founders failed to
ransmit the transgene to their progeny, presumably due
FIG. 1. (A) Schematic representation of the transgene fragment. The c
y interferon, double-stranded RNA, or virus infection. Location of the
mplified fragment are shown. (B) Southern blot analysis of tail DNA fro
f BamHI-digested pssRGD. The last two lanes were loaded with 10 m
RNA in various tissues of a noninduced transgenic mouse and a trans
nalyzed as in B by Southern blot analysis. (D) Western blot analysis oo mosaicism (Wilkie et al., 1986). sIn the course of breeding the transgenic line, we
bserved that the F1 transgenic mice consistently
eighted less than their nontransgenic littermates. The
eight difference was particularly pronounced after
eaning (3 weeks), although the transgenic mice could
e sorted between birth and weaning on the basis of
isual determination of size (Fig. 2). This difference was
tatistically significant and independent of sex. In addi-
ion to the phenotypical dwarf, their reproductive perfor-
ance was very poor, and the ratio of females at birth
as high, suggesting that the presence of the chimeric
gene is under the control of the Mx 1 promoter, which can be induced
s used for RT-PCR of the chimeric gene mRNA and expected size of
sgenic and nontransgenic mice. The first lane was loaded with 100 pg
mHI-digested mouse DNA. (C) RT-PCR analysis of the chimeric gene
ouse induced with double-stranded RNA for 18 h. PCR products were
ung extracts from transgenic and nontransgenic mice treated as in C.
FIG. 2. Retarded growth of transgenic mice. Growth curve of trans-
enic (f) and nontransgenic (F) mice. The values are the averages ofhimeric
primer
m tran
g of Ba
genic meven each of transgenic and nontransgenic mice at the indicated time.
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74 ONO ET AL.ene elicits negative effects during embryogenesis
nd/or after birth.
esistance of the transgenic mice to PRV infection
To determine whether the transgenic mice expressing
he chimeric gene were protected from PRV infection, 2
D50 of PRV was intranasally inoculated into transgenic
nd nontransgenic mice. The survival data (Fig. 3) indi-
ated that the transgenic mice were resistant to PRV. All
f control mice in experiment 1 and 5 of 8 control mice in
xperiment 2 died within 5 days after the virus infection.
n contrast, 8 of 10 transgenic mice (experiment 1) and all
f transgenic animals (experiment 2) survived the viral
noculation and remained healthy for several months
fter this trial. Five of the surviving transgenic mice and
ll of the surviving control mice were sacrificed 14 days
fter the challenge, and the sera were examined for
ntibody titer against PRV. Specific antibodies to PRV in
he samples were detected in all of the surviving trans-
enic mice and the titers were 1:200 to 1:1600, indicating
hat the virus replication occurred in the transgenic mice
nd that the mice were protected from the viral infection.
n contrast, specific antibodies were not detected in the
era of surviving nontransgenic mice, indicating that the
FIG. 3. Resistance to PRV infection in transgenic mice. Transgenic
f) and nontransgenic (F) mice were challenged intranasally with PRV.
rotection tests were performed in duplicate (Expts. 1 and 2). The mice
ere observed for their survival times, which are recorded daily for 7
uccessive days after the challenge.ice were not infected with the virus. suppression of the growth of PRV in cultured
mbryonic fibroblasts from the transgenic mice
To assess whether the in vivo resistance to PRV infec-
ion in the transgenic mice was paralleled by resistance
f their isolated cells, we tested embryonic fibroblasts for
esistance to PRV infection in culture. Transgenic and
ontransgenic fibroblasts treated with interferon were
nfected with 0.01 PFU/cell of PRV. To monitor the virus
rowth in these fibroblasts, the virus titers in the media
ere determined (Fig. 4A). In transgenic fibroblasts, the
irus yield was extensively suppressed (100-fold less in
irus titer than for nontransgenic fibroblasts 4 days
ostinfection). However, there was no difference be-
ween transgenic and nontransgenic fibroblasts without
nterferon treatment (Fig. 4A). To test whether transcrip-
ion of the IE gene is inhibited during PRV infection,
ccumulation of IE mRNA in the PRV-infected and cyclo-
eximide-treated cells was examined by Northern blot
nalysis. As shown in Fig. 4B, transgenic fibroblasts
roduced less IE mRNA than did control fibroblasts. The
ecrease in the IE mRNA level was not due to differ-
nces in the loading of the samples as demonstrated by
-actin hybridization of the same filter. In fibroblasts
erived from transgenic embryos, expression of the fu-
ion protein was induced by treatment with interferon
Fig. 4C). These results indicate that the impediment of
ytic infection of PRV in transgenic fibroblasts is medi-
ted at least in part by inhibition of the PRV IE gene
ranscription by the fusion protein.
DISCUSSION
Pseudorabies inflicts a major economic loss in pig
ndustries worldwide. Vaccination of pigs against PRV
nfection with modified-live virus or inactivated virus in-
uces neutralizing antibodies and sensitized lympho-
ytes in blood and lymphoid organs. Currently available
accines suppress manifestation of the disease but do
ot confer complete protection against the virus infec-
ion. New strategies such as “intracellular immunization”
hould therefore be tried to eradicate the disease. In the
resent study, transgenic mice expressing the chimeric
ene that represses the PRV IE gene transcription
howed significant resistance to PRV infection. This re-
istance was much more striking than that observed in
SV-1-resistant transgenic mouse lines expressing a
utant allele (X25) of ICP4 (Smith and DeLuca, 1992) and
n PRV-resistant transgenic mouse lines expressing the
uman interferon-b1 (Chen et al., 1988). The results of
he present study therefore suggest the potential value of
he chimeric gene in pigs for intracellular immunization
gainst PRV infection.
Consistent with an earlier study (Ono et al., 1995),
ranscription of the PRV IE gene was repressed in the
ransgenic embryonic fibroblasts infected with PRV, re-
ulting in the impediment of lytic infection of PRV. These
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75RESISTANCE TO PRV INFECTION IN TRANSGENIC MICEesults indicate that the resistance of transgenic mice to
RV infection is mediated at least in part by inhibition of
he PRV IE gene transcription by the fusion protein. In the
resent study, transgenic mice were treated with poly
I)–poly(C) before the viral challenge. The treatment may
ffect the viral replication in the transgenic mice. In Vero
ells treated with interferon-a, transcription from the PRV
E promoter was repressed and PRV replication was
uppressed (Tonomura et al., 1996). Furthermore, in vivo
tudies indicated that interferons had important roles for
esistance to PRV infection in mice (Chen et al., 1988;
nodera et al., 1994). Although the susceptibility of non-
ransgenic mice to PRV infection did not change in our
xperiments, we cannot exclude a possibility that the
mmune system induced by the poly(I)–poly(C) treatment
s involved in the observed antiviral activity in the trans-
enic mice. Because the specific antibodies to PRV were
etected in the surviving transgenic mice, the protection
rom PRV infection in transgenic mice was not consid-
red to be complete in the sites of primary infection.
hese findings suggest a possible explanation for the
esistance to PRV infection in transgenic mice. The fu-
ion proteins repress the PRV IE gene transcription in
he sites of primary infection, resulting in suppression of
he viral replication. Because the viral replication is sup-
ressed, spread of the virus in transgenic mice is de-
ayed. In the meantime, the host immune system [includ-
ng interferon induced by the poly(I)–poly(C) treatment
nd/or PRV infection] is evolved to provide protection
rom PRV infection. Consequently, transgenic mice sur-
ive the PRV challenge.
FIG. 4. Resistance to PRV infection in embryonic fibroblasts prepa
repared from transgenic (f) and nontransgenic (F) mice. The virus y
etermined on Vero cell monolayers. (B) Northern blot analysis of IE
ontransgenic mice. Positions of detected IE and b-actin mRNA are
ransgenic and nontransgenic fibroblasts treated with interferon and no
usion protein is indicated on the left.It appears that the chimeric gene may exert adverse tide effects in addition to conferring the desirable char-
cteristic of PRV resistance. First, the transgenic mice
onsistently weighed less than the nontransgenic mice.
imilar findings were observed in the transgenic mice
xpressing the dominant-negative repressor of ICP4 of
SV-1 (Smith and DeLuca, 1992). Second, their reproduc-
ive performance was very poor and the ratio of females
t birth was high. Finally, the expression level of the
himeric gene was very low, which is consisted with the
arlier in vitro study (Ono et al., 1995). Lesser amounts of
ominant-negative repressor in the transfected cells
ere reported in other viral regulatory proteins (Spatz et
l., 1996; Ono et al., 1998a). It is considered that domi-
ant-negative repressors are simply toxic to the cells
nd that the expressions are tightly controlled through a
egative autoregulatory mechanism. To eliminate the
ide effects, a tightly controlled expression system (in-
luding tissue and/or cell specificity, expression time,
nd level) would be necessary. If achievable, the gener-
tion of pseudorabies-resistant animals will be possible.
The surviving transgenic mice had specific antibodies
o PRV. This finding may indicate that the transgenic mice
re latently infected with PRV, although latent infection in
he transgenic mice was not examined. The reactivation
echanism of latently infected PRV has not been eluci-
ated. It has been shown in HSV-1 that ICP0 is required
or the viral reactivation in trigeminal ganglia (Cai et al.,
993; Leib et al.,1989; Zhu et al., 1990). EP0 of PRV has
een reported by Cheung (1991) to be a homolog of ICP0
f HSV-1. EP0 is a viral transactivator of PRV (Watanabe
t al., 1995) and may be important for reactivation from
m transgenic mice. (A) PRV growth curves in embryonic fibroblasts
the interferon-treated (IFN1) and untreated (IFN2) fibrloblasts were
synthesized in embryonic fibroblasts prepared from transgenic and
ted on the right. (C) Western blot analysis of nuclear extracts from
ed transgenic and nontransgenic fibroblasts. Position of the detectedred fro
ields in
mRNA
indica
ninduche latent state (Cheung, 1996). EP0 enhances the PRV IE
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76 ONO ET AL.ene transcription (Watanabe et al., 1995) and the infec-
ivity of PRV genomic DNA (Ono et al., 1998b). EP0 is,
owever, nonessential for PRV replication (Cheung et al.,
994), whereas IE180 is essential (Ihara et al., 1983). It is
herefore conceivable that IE180 is essential for PRV
eplication from the latent state, although EP0 may have
n important role or roles for the first step of reactivation
o activate the IE gene. Because the fusion protein re-
resses PRV IE gene transcription, reactivation from the
atency would be repressed when the chimeric gene is
xpressed in the trigeminal ganglia. The repression
ould occur even when EP0 was expressed in the first
tep of reactivation because transcription of the IE gene
as repressed in cotransfection experiments with the
P0- and the chimeric gene-expression plasmids (Ono et
l., unpublished data). The generation of transgenic mice
epressing PVR IE gene transcription in the trigeminal
anglia would make it possible to prevent reactivation
rom latent infection and hence control the spread of PRV
hroughout a population.
MATERIALS AND METHODS
irus and cells
PRV strain YS-81 and a cellular clone of the porcine
idney cell line (CPK) were kindly provided by M. Shimizu
National Institute of Animal Health, Tsukuba, Japan).
ero cells were a generous gift from M. Peeples (Rush
niversity, Chicago, IL). CPK cells, grown in Eagle’s min-
mum essential medium supplemented with 10% calf
erum, 0.03% L-glutamine, 0.03% tryptose phosphate
roth, nonessential amino acids (Flow Laboratories,
osta Mesa, CA), vitamins (Flow Laboratories), 100 U/ml
enicillin, and 0.1 mg/ml streptomycin, were used for
ropagation of the virus. Vero cells, grown in RPMI 1640
edium supplemented with 5% FBS, 0.03% L-glutamine,
00 U/ml penicillin, and 0.1 mg/ml streptomycin, were
sed to titer the virus as described previously (Ono et al.,
995).
Embryonic fibroblasts were isolated by dicing 14-day-
ld mouse embryos, stirring the pieces for 30 min at
oom temperature in PBS, supplementation with 0.25%
rypsin, and then plating out the resulting single cell
uspension. The cells were grown in Dulbecco’s modi-
ied Eagle’s medium (DMEM; GIBCO BRL, Gaithersburg,
D) supplemented with 10% FBS and the above antibi-
tics. The cells were passed no more than twice before
se.
ransgenic mice
The BamHI linker was inserted into the HindIII site
nd-filled with a large fragment of DNA polymerase I to
btain a BamHI fragment encoding the fusion protein
rom pcRGD (Ono et al., 1995). Plasmid pSS-2-2 (Mitchell
t al., 1993) containing the Mx 1 promoter (Hug et al., l988) and the mouse b-globin sequence (Konkel et al.,
978) cloned into pSP65 was linealized at the single
amHI site at the junction between the promoter and the
-globin sequence. The linealized plasmid and the
amHI fragment containing the chimeric gene were li-
ated. The resulting plasmid was designated pssRGD.
he 5.2-kb XbaI fragment (Fig. 1A) from the construct was
solated and purified, and approximately 500 copies
ere microinjected into the pronuclei of fertilized
57BL/6 mouse embryos. They were transplanted into
he oviducts of pseudopregnant females as described by
amamura et al. (1984).
Transgenic founders were identified by Southern blot
nalysis (Southern, 1975) using genomic DNA isolated
rom mouse tail (Hogan et al., 1986). The DNA samples
10 mg) were digested with BamHI, fractionated on 0.8%
garose gel, and transferred to a Hybond-N1 membrane
Amersham Life Science, Buckinghamshire, England).
igoxigenin (DIG)-labeled oligoprobes for detection of
he transgene were derived from a 1.8-kb HindIII–BamHI
ragment of pcRGD using a DIG DNA labeling kit (Boeh-
inger Mannheim Biochemica, Mannheim, Germany). Hy-
ridization and detection of the transgene were per-
ormed using a DIG nucleic acid detection kit and CSPD
Boehringer Mannheim Biochemica) as directed by the
anufacturer except that hybridized membranes were
ashed at 68°C instead of 42°C.
nalysis of transgene expression
Transgenic mice were injected intraperitoneally with
0 mg of poly(I)–poly(C) (Wako Pure Chemical Industries,
saka, Japan) or left untreated. Eighteen hours after the
nduction, total RNA was isolated from various tissues of
he transgenic mice using TriZOL reagent (GIBCO BRL).
o detect the chimeric gene-specific mRNA, the total
NA was amplified by RT-PCR to obtain a fragment of
SV-1 VP16 coding region. The cDNA was synthesized
rom 10 mg of the total RNA by Moloney murine leukemia
irus reverse transcriptase (GIBCO BRL) using oligo(dT)18
s a primer at 42°C for 1 h. The primers used to identify
he transgene expression were 59-CTATCGAACCGTGTT-
GCCAACTT-39 and 59-ATCAACACCATAAAGTACCCA-
AG-39, which resulted in the generation of a 519-bp
SV-1 VP16 cDNA fragment (Fig. 1A). PCR was per-
ormed by 30 reaction cycles. A single cycle consisted of
hree reactions: denaturation at 94°C for 1 min, anneal-
ng at 58°C for 3 min, and extension at 72°C for 3 min.
he PCR products were fractionated on 1% agarose gel
nd analyzed by Southern blot analysis as described
bove.
Western blotting was performed according to the
ethod of Towbin et al. (1979). Transgenic and nontrans-
enic mice were injected intraperitoneally with 50 mg of
oly(I)–poly(C). Eighteen hours after the induction, totalung extracts were prepared in 100 mM 2-(N-morpholino)
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77RESISTANCE TO PRV INFECTION IN TRANSGENIC MICEthanesulfonic acid, 1 mM EGTA, and 0.5 mM MgSO4
pH 6.9). Aliquots of the extracts were adjusted for equal
rotein content and separated by 12% SDS–PAGE. The
eparated proteins were then electrophoretically trans-
erred to a nitrocellulose sheet. The sheet was treated
equentially with a Block Ace (Yukijirushi), 500-fold di-
uted anti-HSV-1 VP16 monoclonal antibody LP1
McLean et al., 1982), and finally with peroxidase-labeled
oat anti-mouse IgG (BioRad, Hercules, CA). The antigen
as detected using Renaissance Reagent (DuPont NEN
esearch Products, Boston, MA) as a substrate.
irus infection in mice
Transgenic and nontransgenic mice were used when
hey were 8–10 weeks old. To induce the chimeric gene
xpression, transgenic mice were injected intraperitone-
lly with 50 mg of poly(I)–poly(C). Eighteen hours after the
nduction, the transgenic mice were infected intranasally
ith 5 ml of PBS containing 2 LD50 (viral dose titered on
57BL/6 that was required to produce death in 50% of
est animals) of PRV under anesthesia. Deaths of mice
ere recorded for 14 days. Nontransgenic mice were
sed as controls.
Anti-PRV antibodies in sera of surviving mice were
easured by ELISA (Kida et al., 1982). Disrupted viral
ntigen was prepared from purified PRV (Ono et al.,
998b).
irus infection in mouse embryonic fibroblasts
Mouse embryonic fibroblasts were plated at a subcon-
luent density on 60-mm dishes. The following day, the
ells were treated with 1000 U of recombinant mouse
nterferon-aA/ml for 18 h. After the induction, 0.01 PFU/
ell of PRV was adsorbed onto the cells. After 1 h, the
ells were washed twice with DMEM and then main-
ained in 5 ml of DMEM. Supernatant was removed at
4-h intervals. Virus titers of supernatant samples were
etermined on Vero cell monolayers.
To express PRV IE mRNA selectively, cells that were
reated with mouse interferon-aA as described above
ere treated with cycloheximide (50 mg/ml) for 1 h before
nfection with PRV at 10 PFU/cell. Infection and mainte-
ance were performed in the presence of the drug. Total
ellular RNA was isolated from the cells using an RNA
solation kit (Stratagene Cloning Systems, La Jolla, CA).
RNA isolation was performed using an mRNA separa-
or kit (Clontech, Palo Alto, CA). Purified mRNA samples
10 mg) were electrophoresed on a formaldehyde-con-
aining 1% agarose gel and blot-transferred to a Hy-
ond-N1 membrane. DIG-labeled riboprobes were de-
ived from pc/IE (Taharaguchi et al., 1994) using the DIG
NA labeling kit. DIG-labeled b-actin probe was pur-
hased from Boehringer Mannheim Biochemica for the
etection of b-actin mRNA. Hybridization and detectionf PRV IE and b-actin mRNA were performed as de-
cribed previously by Ono et al. (1995).
To detect the fusion protein, mouse embryonic fibro-
lasts were plated at a subconfluent density onto
00-mm dishes. The following day, the cells were treated
ith 1000 U of recombinant mouse interferon-aA (Pestka
iomedical Laboratories)/ml for 18 h. After the induction,
uclear extracts were prepared from the mouse embry-
nic fibroblasts according to the methods of Schreiber et
l. (1989). Aliquots of the nuclear extracts were adjusted
or equal protein content and were applied onto 12%
DS–polyacrylamide gels and electrophoresed. Western
lotting was performed as described above.
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